A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy

NCT06769113 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Cancer

Interventions

DRUG: HLX43

Sponsor

Shanghai Henlius Biotech